Shots:

• eFFECTOR to get $15M up front- $492M R&D funding- development and sales milestone payments- plus royalties on sales of product and has an option to co-promote with equal profit/loss sharing in the US. Pfizer to get exclusive WW rights to license to develop eFFECTOR’s eIF4E for multiple cancer indications
• The focus of the agreement is to combine eFFECTOR’s development capabilities and Pfizer’s global commercial resources to develop eIF4E inhibitor therapies for cancer patients
• eIF4E (eukaryotic initiation factor 4E) is an effector protein that integrates signals from multiple oncogenes and tumor suppressor proteins in the PI3K and RAS oncogenic pathways (including PI3K- AKT- mTOR- PTEN and BRAF) and regulates the translation of mRNA from those regulated by MNK1/2 and eIF4A

Click here to read full press release/ article | Ref: eFFECTOR | Image: Signbox